Shiono Opiyaku stock plummeted, trial expectations for obesity treatment drugs were disappointing and Jeffries

Shiono Yakuyaku has a weight loss rate of 5% or less and cannot advance to phase 3 with a single agent.
The stock price fell 16% at one point, reaching an intraday low level for the first time in about 10 months.
The stock price of Shionogi Pharmaceutical fell 16% at one point, hitting an intraday low since August 8 last year. In a phase 2 clinical trial of obesity treatment drug candidates, it was shown on the 6th that the weight loss rate (group average) did not exceed 5%, and a sense of disappointment is spreading.